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The increased cancer incidence may result from immunological deficiencies in patients with sarcoidosis.
ACCORDING to the theories of immunological surveillance in the human body, an intact immune apparatus is one of the conditions necessary to prevent or limit the development of malignant tumours. Thus a certain number of congenital, idiopathic or iatrogenic disturbances of the immune apparatus are known to be associated with an increased incidence of cancer, particularly of malignant lymphomata (Keast, 1970; Doll and Kinlen, 1970) .
Since various immunological disturbances usually accompany sarcoidosis (Chase, 1966) , it might be reasoned that this disease could be associated with an increased incidence of malignant tumours, but studies of the incidence of malignancies in large series of sarcoidosis patients have apparently not been published. Case histories which show an association between sarcoidosis and malignant lymphomata or lung cancer have been reviewed by Brincker (1972) and Sakula (1963) . These studies did not allow estimation of the frequency of the association of sarcoidosis with a malignancy. However, in Brincker's study (1972) 5 cases of true sarcoidosis were found in about 1500 cases of malignant lymphoma. This rate is very high in view of the fact that sarcoidosis occurs with an incidence of 5 per 100,000 in the general population (Horwitz, 1967; Horwitz, Payne and Wilbek, 1967 (Alsbirk, 1964; R0mer et al., 1973) . The unreported cases probably represent more severe symptomatic forms of the disease.
Clinical and epidemiological data of the sarcoidosis patients reported to DICE have been described in detail elsewhere (Clemmesen, 1965) .
During the decade 1962-71, 2561 newly diagnosed cases of respiratory sarcoidosis were reported to the central register. In September 1972 all the notifications were matched against the files of the Cancer Registry in order to see which sarcoidosis patients had a record in the Cancer Registry. All cases of cancer which had occurred before 1 January 1972 were registered and from the search through the records it was found that 65 patients had been registered with a malignant disease.
In 17 patients the tumour was demonstrated before the diagnosis of sarcoidosis and they were therefore excluded. In the remaining 48 patients the malignancy was diagnosed simultaneously with, or after, sarcoidosis and the present study consists of those patients. The basic population thus consists of 2544 patients (1292 males and 1252 females) with sarcoidosis, who had not had cancer previously. Table I shows the distribution of the 48 cancer cases by diagnosis; none of the patients In order to calculate the expected number of cancer cases, the sarcoidosis patients were broken down by year of report, i.e., those reported in 1962, 1963 etc.; within each of these groups, the patients were split by sex and age. The sex and age specific incidence of cancer in the Danish general population (average for 1963-67) was applied to each of these cells. Although the entire observation period 1962-71 is not covered by the 1963-67 cancer incidence rates, the latter were used for the calculations because they represent the latest available Danish figures (Clemmesen. 1973, personal communication) . The expected number depends, of course, on the length of the period at risk. The onset of this period was reckoned from the year that the sarcoidosis was reported in the register, and runs up to 1 January 1972; the period was thus on an average 91 years for those reported in 1962, 81 years for those reported in 1963 and so on, until for those reported in 1971 it was half a year. When the calculations were made, regard was also paid to the factor that the patient's age increased during the period of observation. The expected number of all forms of cancer taken together was calculated but special estimates were made for lung cancer and malignant lymphoma, based on the respective rates for the two diseases.
The following formula has been used to calculate the significance levels: No review was made of the case records in order to check the diagnosis of any of the 48 patients who had both sarcoidosis and cancer; a rejection of the diagnosis in one or more of these cases would merely result in a statistically unacceptable alteration in the basis for the calculations. Table II shows that 48 cases of cancer were observed, whereas only 33.8 cases were expected. This difference is statistically significant (0-02 >P > 0 01). The higher incidence is due primarily to an increased number of cases in males, particularly of lung cancer. Nine cases of lung cancer were found but only 2-8 cases were expected; this difference is highly significant (P < 0 001). Six cases of malignant lymphoma occurred whereas only 0 5 cases were expected; this difference is also highly significant (P < 0 001). With regard to all other forms of cancer, there is no significant difference between the expected and the observed number of cases (30.5 cases vs 33). other words, the number of patients at risk is high for short intervals and decreases the longer the interval becomes. The expected incidence goes up gradually because the patients' age increases during the observation period; hence the risk of cancer also increases. It is striking that the observed cancer incidence is very high during the first 4 follow-up years; thereafter it drops to the normal level or per- (Sakula, 1963) or malignant lymphomata (Brincker, 1972) ; this reaction should not be considered as sarcoidosis disease.
RESULTS
If we assume that patients with respira-tory sarcoidosis really have an increased frequency of lung cancer and malignant lymphomata, it is natural to ask why this is so. As regards lung cancer, the chronic pulmonary changes caused by sarcoidosis may act as an additional carcinogenic stimulus; it may also be that these changes lead to a decreased resistance to other carcinogenic stimuli. The increased incidence of malignant lymphomata may result from the immunological defects often noted in sarcoidosis patients; this is in line with the increased incidence of malignant lymphomata in patients who have immunological defects (Keast, 1970; Doll and Kinlen, 1970 Since the present study is based on information from matching between two central registries, the question may be posed whether or not the incidence of malignant tumours in the sarcoidosis patients is too low because of a reporting deficit. As mentioned previously, the reporting deficit concerning the malignant disease is negligible and plays no role. As regards sarcoidosis, the moderate reporting deficit might at first sight seem of no importance since the basis of the study is those cases which were in fact reported. However, the most severe cases of sarcoidosis are probably not reported to DICE as they are treated only in the medical departments. The present series is therefore likely to be dominated by the findings in mild, non-symptomatic cases. Such patients may have higher immunity and therefore also a lower cancer risk, if the incidence of malignant tumours is proportional to the degree of the immunological defect, and hence also the severity of the sarcoidosis. As the mild cases constitute about half of the present series, this might explain why the increased incidence of cancer was confined to lung cancer and malignant lymphomata. This hypothesis is supported by the fact that patients with symptomatic sarcoidosis had an observed cancer incidence which was 1-5 times higher than expected; among the non-symptomatic cases the ratio was only 1*2 times higher (see Table II ). Thus, this fact also supports the assumption and previously quoted data indicating that a genuine association exists between cancer and sarcoidosis.
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